Clinical trials: Lipemia
Hypercholesterolemia
Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)
Evaluate the proportion of hyperlipaemic persons with known coronary heart disease achieving ldl-c goal as defined by the national cholesterol education program (NCEP) adult treatment panel (ATP) III guidelines
- Trial name
- NCT00442897
- Testing
- simvastatin (+) ezetimibe, Comparator: atorvastatin
- Volunteers
- 229 people
- Sponsor
- Organon and Co
Hyperlipidemia
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneously once every 2 weeks (Q2W) and once monthly (QM), compared with placebo, on percent change from baseline in low-density lipoprotein…
- Trial name
- RUTHERFORD-2 (NCT01763918)
- Testing
- Evolocumab
- Where
- 39 sites in United States, Australia and 12 more
- Volunteers
- 331 people
- Sponsor
- Amgen
Hyperlipidemia and Mixed Dyslipidemia
Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia
This study will contribute to the evaluation of long-term safety, tolerability and efficacy of evolocumab (AMG 145) in adults with hyperlipidemia and adults with mixed dyslipidemia.
- Trial name
- OSLER-2 (NCT01854918)
- Testing
- Evolocumab, Standard of Care
- Where
- 363 sites in United States, Australia and 23 more
- Volunteers
- 3,681 people
- Sponsor
- Amgen
Hyperlipidemia
Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin
The purpose of the study is to evaluate the safety and tolerability of multiple doses of evolocumab when given as an add-on to stable statin therapy.
- Trial name
- NCT01133522
- Testing
- Evolocumab
- Volunteers
- 60 people
- Sponsor
- Amgen
Obesity, Hypercholesterolemia
Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults
This study aims to 1) assess the feasibility and acceptability of a prescribed beverage intervention in 50 obese Hispanic adults ages 18-64 years over 6 weeks; and 2) assess preliminary effects of the beverage intervention on…
- Conditions
- Obesity, Hypercholesterolemia, Hyperglycemia, Hypertriglyceridemia
- Trial name
- NCT02911753
- Testing
- Mediterranean Lemonade, Green Tea, Flavored Water
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Lipodystrophy
Leptin to Treat Lipodystrophy
This study will evaluate the safety and effectiveness of leptin replacement therapy in patients with lipodystrophy (also called lipoatrophy). Patients have a total or partial loss of fat cells.
- Trial name
- NCT00025883
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hypertriglyceridemia, Inflammation
Impacts of Lentils on Metabolism and Inflammation
The overall goal of this investigation is to determine gut microbiome dependent and independent impacts of pulse consumption on metabolic resilience and metabolic risk profiles for type 2 diabetes (T2D) and cardiovascular disease…
- Conditions
- Hypertriglyceridemia, Inflammation, Waist, Hypertriglyceridemic
- Trial name
- NCT04283448
- Testing
- Dietary Lentil, Control
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Montana State University
Hyperlipidemia
Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans
The hypothesis of this study is that the natural supplement Capros will decrease LDL levels, platelet aggregation, and serum concentrations of high sensitivity C-reactive protein in humans at risk for cardiovascular disease.
- Trial name
- Capros (NCT01858376)
- Testing
- Capros dietary supplement
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chandan K Sen
Dyslipidemias, Hyperlipidemias
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
This is a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy, safety, tolerability, and pharmacokinetics (PK) of PF-07285557 (hereafter, vupanorsen) administered…
- Conditions
- Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias
- Trial name
- NCT04516291
- Testing
- Vupanorsen
- Where
- 114 sites in United States, Canada and 1 more
- Volunteers
- 286 people
- Sponsor
- Pfizer
Hyperlipidemias
Lipid Management in Renal Transplant Recipients Using Evolocumab.
Cardiovascular disease is the leading cause of mortality after renal transplantation, accounting for more than 30% of deaths. Elevated lipid levels (hyperlipidemia) are a frequent finding following transplantation and the…
- Trial name
- NCT04608474
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Brigham and Women's Hospital
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Effect of Diabetes Mellitus on Cholesterol Metabolism
HMG CoA reductase inhibitors (statins) are commonly used to treat high cholesterol (HC) in both type 1 and type 2 diabetes mellitus (DM).
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hypercholesterolemia
- Trial name
- NCT00879710
- Testing
- simvastatin or ezetimibe
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Medical College of Wisconsin
Hypercholesteremia
Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)
The purpose of this study was to assess the efficacy, safety, and tolerability of multiple doses of Gemcabene in patients with HoFH on stable, lipid-lowering therapy.
- Trial name
- NCT02722408
- Testing
- Gemcabene
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 8 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)
This study will assess the safety and tolerability of Ezetimibe (EZ) 10 mg/Atorvastatin (Atora) 10 mg and EZ 10mg/Atora 20 mg fixed-dose combination (FDC) in Japanese participants with hypercholesterolemia uncontrolled with…
- Trial name
- NCT02460159
- Testing
- EZ 10 mg/Atorva 20 mg FDC, EZ 10 mg/Atorva 10 mg FDC
- Volunteers
- 135 people
- Sponsor
- Organon and Co
Homozygous Familial Hypercholesterolemia
Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities
A study to determine the safety, tolerability, and efficacy of evolocumab (AMG 145) in patients with homozygous familial hypercholesterolemia (HoFH).
- Trial name
- TESLA (NCT01588496)
- Testing
- Evolocumab
- Where
- 21 sites in United States, Belgium and 10 more
- Volunteers
- 58 people
- Sponsor
- Amgen
Primary Hypercholesterolemia, Mixed Dyslipidemia
Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen
The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in home-use using either a pre-filled syringe or autoinjector/pen.
- Trial name
- NCT01849497
- Testing
- Evolocumab Pre-filled Syringe, Evolocumab AI/pen
- Where
- 26 sites in United States, Canada
- Volunteers
- 149 people
- Sponsor
- Amgen
Severe Hypertriglyceridemia
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
The purpose of AROAPOC3-2001 is to evaluate the efficacy and safety of ARO-APOC3 in participants with severe hypertriglyceridemia. Participants will receive 2 subcutaneous injections of ARO-APOC3.
- Trial name
- SHASTA-2 (NCT04720534)
- Testing
- ARO-APOC3
- Where
- 74 sites in United States, Australia and 6 more
- Volunteers
- 229 people
- Sponsor
- Arrowhead Pharmaceuticals
High Cholesterol
Effect of Policosanol as Monotherapy and Adjunctive to Statin Therapy
To determine the effects of policosanol on the cholesterol profile.
- Trial name
- NCT00510809
- Testing
- Policosanol, Policosanol Plus Already In Use Statin Therapy
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- James Backes, PharmD
Chronic Kidney Disease, High Cholesterol
The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney Disease
The purpose of this study is to see if patients with chronic kidney disease have endothelial cells that don't function properly, which is thought to be a marker for cardiovascular risk.
- Trial name
- NCT02133534
- Testing
- Atorvastatin
- Volunteers
- 1 people
- Sponsor
- Duke University
Hypertriglyceridemia
Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL
The primary objective is to determine the efficacy of AMR101 (ethyl icosapentate) compared to placebo in lowering fasting triglyceride levels in patients with very high fasting triglyceride levels ≥ 500 and ≤ 2000 mg/dL.
- Trial name
- MARINE (NCT01047683)
- Testing
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day
- Where
- 60 sites in United States, Denmark and 9 more
- Volunteers
- 229 people
- Sponsor
- Amarin Pharma Inc.
Familial Hypercholesterolemia
Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
The main purpose of this study is to describe the safety and tolerability of 80 weeks of subcutaneous (SC) evolocumab when added to standard of care in children 10 to 17 years of age with familial hypercholesterolemia.
- Trial name
- HAUSER-OLE (NCT02624869)
- Testing
- Evolocumab
- Where
- 46 sites in United States, Australia and 21 more
- Volunteers
- 163 people
- Sponsor
- Amgen